Mayne Pharma Continues To Look At Potential Acquisitions

mayne pharma

Mayne Pharma has grown rapidly, going from relative obscurity just four years ago to one of the top 25 generic drug companies in North America. Mayne Pharma has continually grown by targeting acquisitions, as it did last month when it purchased 42 generic drugs from Allergan and Teva. Both companies are participating in their own merger and are facing antitrust pressure to divest certain generic drug products.  Mayne Pharma continues to look at strategic acquisitions, which had made the company an attractive business for investors.

Read the source article at Financial Review

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>